Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,827
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,203.90 | 28.80 | 0.35% |
CAC 40 | 7,606.75 | 70.49 | 0.94% |
DAX 40 | 22,379.55 | 137.10 | 0.62% |
Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
FTSE 100 | 8,434.96 | 19.71 | 0.23% |
HKSE | 21,971.96 | 8.78 | -0.04% |
NASDAQ | 17,382.94 | 216.90 | 1.26% |
Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
S&P 500 | 5,525.21 | 0.00 | 0.00% |
S&P/ASX 200 | 7,997.10 | 28.90 | 0.36% |
SSE Composite Index | 3,288.41 | 6.65 | -0.20% |